Advertisement

Topics

Biotech Startup Akrevia Therapeutics Lands $30M to Develop Next-Gen cancer immunotherapies

08:13 EDT 28 Sep 2018 | HIT Consultants

  Akrevia Therapeutic, a Cambridge, MA-based biotech startup focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics has raised $30 million in funding led by F-Prime Capital Partners and Atlas Venture. The funding will be used to accelerate Akrevia’s pipeline and proprietary Aklusion® platform, which allows therapeutic antibodies, cytokines and chemokines to be specifically activated in the ... Read More

Original Article: Biotech Startup Akrevia Therapeutics Lands $30M to Develop Next-Gen cancer immunotherapies

NEXT ARTICLE

More From BioPortfolio on "Biotech Startup Akrevia Therapeutics Lands $30M to Develop Next-Gen cancer immunotherapies"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...